Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Japan News/Yomiuri
The Japan News/Yomiuri
National
Kiyohiko Yoneyama and Chisato Yomon / Yomiuri Shimbun Staff Writers

Insufficient proof behind rejection of Shionogi COVID-19 drug

Experts discuss the emergency approval of Xocova as a COVID-19 pill during a health ministry meeting in Tokyo on Wednesday. (Credit: The Yomiuri Shimbun)

A COVID-19 pill developed by Shionogi & Co. has failed to win fast-track emergency approval because experts sought scientifically convincing data to prove its efficacy, rather than focusing on the need for more treatment options amid the seventh wave of novel coronavirus infections.

The decision not to approve Xocova as the first domestically produced pill for COVID-19 patients with mild to moderate symptoms was made at a joint meeting Wednesday of subgroups of the Health, Labor and Welfare Ministry's Pharmaceutical Affairs and Food Sanitation Council.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.